Michele B. Kaufman, PharmD, BCGP | Issue: January 2018 |
E6011, an anti-fractalkine monoclonal antibody, proved promising for the treatment of rheumatoid arthritis during a 52-week clinical trial…
New research demonstrates that subcutaneous tocilizumab monotherapy may preserve disease control in RA patients who have discontinued methotrexate…
For patients with rheumatoid arthritis (RA) who respond to subcutaneous tocilizumab, discontinuing methotrexate may be an option and offer an alternative to patients who cannot tolerate or prefer not to take methotrexate. “This is one of the first studies showing that methotrexate may be discontinued in a cohort of patients with a biologic agent without…
For patients with refractory Takayasu arteritis (TAK), glucocorticoids (GCs) are often provided as the initial therapy for treatment. However, GCs are often associated with adverse effects for long-term use; relapse also occurs frequently during GC tapering.1 TAK involves interleukin (IL) 6. Tocilizumab—a recombinant, humanized, anti-IL-6 receptor (IL-6R) monoclonal antibody—was first reported by Nishimoto et al….